At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 910 enrolled
Drug / intervention
MenACWY-CRM Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Single-blind, Controlled, Single-Center Study to Compare the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Children 2-10 Years of Age and an Open-label Study to Assess the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine Administered to Healthy Toddlers 12-23 Months of Age
In Brief
A Phase 2 clinical trial evaluating MenACWY-CRM Vaccine and MenACWY-PS Vaccine for Prevention of Meningococcal Disease. Completed, enrolled 910 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy children ages 1 - 10 years
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrevention of Meningococcal Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2005
First PostedDec 2005
Primary CompletionNov 2006
TodayJul 2026
First PostedDec 6, 2005
Enrollment StartApr 1, 2005
Primary CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 20.6 years ago
Interventions
MenACWY-CRM Vaccinebiological
MenACWY-PS Vaccinebiological